Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-α or TNF-related apoptosis-inducing ligand in human cancer cell lines

Cancer Research

Volumn 63, Issue 3, 2003, Pages 621-626

  Kim, Dong Myung ^a   Koo, Sun Young ^a   Jeon, Kiwan ^a   Kim, Min Hyung ^a   Lee, Jinho ^a   Hong, Chang Yong ^a   Jeong, Shin Wu ^a  

^a LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CHROMOSOME DAMAGE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT INDICATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, SMALL CELL; CASPASES; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; FIBROBLASTS; FLAVONOIDS; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; PIPERIDINES; RATS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037311226     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., and Vokes, E. E. Flavopiridol a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II consortium study. J. Clin. Oncol., 18: 371-375, 2000.
2. Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., Werner, J., Perkins, P., Stoltz, M., and Kelsen, D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol., 19: 1985-1992, 2001.
3. Shapiro, G. I., Supko, J. G., Patterson, A., Lynch, C., Lucca, J., Zacarola, P. F., Muzikansky, A., Wright, J. J., Lynch, T. J., Jr., and Rollins, B. J. A Phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin. Cancer Res., 7: 1590-1599, 2001.
4. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of CDC2 kinase activity by the flavopiridol L86-8275. Biochem. Biophys. Res. Commun., 201: 589-595, 1994.
5. Carlson, B. A., Pearlstein, R. A., Naik, R. G., Sedlacek, H. H., Sausville, E. A., and Worland, P. J. Inhibition of CDK2, CDK4, and CDK7 by flavopiridol and structural analogues. Proc. Am. Assoc. Cancer Res., 37: 424, 1996.
6. 1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
7. Sedlacek, H. H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., and Sausville, E. Flavopiridol (L86 8275; NSC649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol., 9: 1143-1168, 1996.
8. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Gen. Biol., 2: research0041.1-0041.11, 2001.
9. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sauville, E. A., and Senderowicz, A. M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4641, 1999.
10. Bible, K. C., Bible, R. H., Jr., Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y. P., Hajdu, E., and Kaufmann, S. H. Flavopiridol binds to duplex DNA. Cancer Res., 60: 2419-2428, 2000.
11. Li, W., Fan, J., and Bertino, J. R. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res., 61: 2579 -2582, 2001.
12. Bible, K., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol(NSC649890. L86-8275) and various antineoplastic agents: importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997.
13. Schwartz, G. K., Farsi, K., Maslak, P., Kelsen, D. P., and Spriggs, D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res., 3: 1467-1472, 1997.
14. Motwani, M., Delohery, T. M., and Schwartz, G. K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 5: 1876-1883, 1999.
15. Schwartz, G. K., Kaubisch, A., Saltz, L., Ilson, D., O'Reily, E., Baraz-zuol, J., Endres, S., Saltz, M., Tong, W., Spriggs, D., and Kelsen, D. P. Phase I trial of sequential paclitaxel and the cyclin-dependent kinase inhibitor flavopiridol. Proc. Am. Soc. Clin. Oncol., 18: 614, 1999.
16. Lienard, D., Ewalenko, P., Delmotte, L. J., Renard, N., and Lejeune, F. J. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan on isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52-60, 1992.
17. Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N(CD13). Nat. Biotech., 18:1185-1191, 2000.
18. Beg, A. A., and Baltimore, D. An essential role for NF-kB in preventing TNF-α-induced cell death. Science (Wash. DC), 274: 782-784, 1996.
19. Wang, C-Y., Mayo, M. W., and Baldwin, A. S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Wash. DC), 274: 784-787, 1996.
20. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. Suppression of TNF-α-induced apoptosis by NF-κB. Science (Wash. DC), 274: 787-789, 1996.
21. Das, K. C., and White, C. W. Activation of NF-kB by antineoplastic agents. J. Biol. Chem., 272: 14914-14920, 1997.
22. Cusack, J. C., Liu, R., and Baldwin, A. S. Inducible chemoresistance to 7-ethyl-10-(4-(1-piperidino)-1-piperidino)-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res., 60: 2323-2330, 2000.
23. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., Deforge, L., Schow, P., Hooley, J., Sherwood, S., Pai. R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A., Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., and Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nature (Lond.), 7: 383-385, 2001.
24. Keane, M. M., Rubinstein, Y., Cuello, M., Ettenberg, S. A., Banerjee, P., Nau, M. M., and Lipkowitz. S. Inhibition of NF-kB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res. Treat., 64: 211-219, 2000.
25. Shapiro, G. I., Koestner, D. A., Matranga, C. B., and Rollins, B. J. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res., 5: 2925-2938, 1999.
26. Nicholson, D. W. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis. Nature (Lond.), 14: 297-301, 1996.
27. Ozoren, N., Kim, K., Burns, T. F., Dicker, D. T., Moscioni, A. D., and El-Diery, W. S. The caspase 9 inhibitor z-LEHD-fmk protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res., 60: 6259-6265, 2000.
28. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
29. Cartee, L., Smith, R., Dai, Y., Rahmani, M., Rosato, R., Almenara, J., Dent, P., and Grant, S. Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways. Mol. Pharmacol., 61: 1313-1321, 2002.
30. Cheng, Q., Lee, H. H., Li, Y., Parks, T. P., and Cheng, G. Up-regulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kB inhibition. Oncogene, 19: 4936-4940, 2000.
31. Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. D., and Baldwin, A. S. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol., 19: 5785-5799, 1999.